Sage Faces Multiple Moments Of Truth For Zuranolone, GABA Modulation

Three pivotal studies reading out in 2021 could redeem Sage Therapeutics, Inc.’s zuranolone (SAGE-217) following its failure in the acute treatment of major depressive disorder at the end of last year. Before then, however, Phase II results for its next-generation drug SAGE-324 in chronic treatment of essential tremor could reinforce the company’s confidence in its GABA-modulation approach to mood and movement disorders.

Three Phase III clinical trials of zuranolone are under way in two different major depressive disorder (MDD) settings and in postpartum depression (PPD) with results due next year. Top-line data...